These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21525976)

  • 1. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).
    Abbas UL; Hood G; Wetzel AW; Mellors JW
    PLoS One; 2011 Apr; 6(4):e18165. PubMed ID: 21525976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.
    Abbas UL; Anderson RM; Mellors JW
    PLoS One; 2007 Sep; 2(9):e875. PubMed ID: 17878928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do mathematical models tell us about the emergence and spread of drug-resistant HIV?
    Baggaley RF; Powers KA; Boily MC
    Curr Opin HIV AIDS; 2011 Mar; 6(2):131-40. PubMed ID: 21505388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness.
    Dimitrov D; Boily MC; Brown ER; Hallett TB
    PLoS One; 2013; 8(11):e80927. PubMed ID: 24282559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
    van de Vijver DA; Boucher CA
    Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.
    Dimitrov DT; Boily MC; Hallett TB; Albert J; Boucher C; Mellors JW; Pillay D; van de Vijver DA
    PLoS One; 2016; 11(7):e0158620. PubMed ID: 27391094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Resistance During HIV Pre-Exposure Prophylaxis.
    Gibas KM; van den Berg P; Powell VE; Krakower DS
    Drugs; 2019 Apr; 79(6):609-619. PubMed ID: 30963509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study.
    Bershteyn A; Sharma M; Akullian AN; Peebles K; Sarkar S; Braithwaite RS; Mudimu E
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis.
    Volk JE; Nguyen DP; Hare CB; Marcus JL
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):329-330. PubMed ID: 29262689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are current guidelines adapted for patient eligibility to PrEP? A case report.
    Van Obberghen EK; Viard D; Lafeuillade A; Civiletti A; Rocher F; Drici MD
    BMC Infect Dis; 2019 Jul; 19(1):601. PubMed ID: 31291899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance.
    Supervie V; Barrett M; Kahn JS; Musuka G; Moeti TL; Busang L; Blower S
    Sci Rep; 2011; 1():185. PubMed ID: 22355700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?
    Hurt CB; Eron JJ; Cohen MS
    Clin Infect Dis; 2011 Dec; 53(12):1265-70. PubMed ID: 21976467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.
    Supervie V; García-Lerma JG; Heneine W; Blower S
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12381-6. PubMed ID: 20616092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study.
    Masyuko S; Mukui I; Njathi O; Kimani M; Oluoch P; Wamicwe J; Mutegi J; Njogo S; Anyona M; Muchiri P; Maikweki L; Musyoki H; Bahati P; Kyongo J; Marwa T; Irungu E; Kiragu M; Kioko U; Ogando J; Were D; Bartilol K; Sirengo M; Mugo N; Baeten JM; Cherutich P; PrEP Technical Working Group OBOT
    Sex Health; 2018 Nov; 15(6):578-586. PubMed ID: 30408432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.